Researcher Spotlight: Haopeng Yang, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Super-enhancers are regions of the genome responsible for regulating expression of an unusually high number of genes. For his Lymphoma Research Foundation-funded project, Dr. Yang is characterizing the…
Researcher Spotlight: Min Xia, PhD WEILL CORNELL MEDICINE Among the different subtypes of diffuse large B-cell lymphoma (DLBCL), ABC-DLBCL represents one of the most aggressive forms with low response rates to standard chemotherapeutic approaches. Improved treatment approaches in this space…
Researcher Spotlight: Danielle Wallace, MD UNIVERSITY OF ROCHESTER Mindy Camp Fedida Memorial Scholar Older patients with diffuse large B-cell lymphoma (DLBCL) are often treated with lower doses of chemotherapy, which may contribute to an incomplete cure of the disease. Residual…
Researcher Spotlight: Jordan Goldstein, MD STANFORD UNIVERSITY Errol M. Cook Memorial Scholar Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma, with many patients experiencing relapse after first-line therapy. Many patients now receive treatment with a chimeric…
Researcher Spotlight: Brian Sworder, MD, PhD Stanford University School of Medicine Chimeric antigen receptor (CAR) T cells have shown to be incredibly beneficial for patients with lymphomawho have relapsed after chemotherapy. Unfortunately, however, several patients will still go on to relapse after…
Researcher Spotlight: Coraline Mlynarczyk, PhD Joan & Sanford I. Weill Medical College of Cornell University Diffuse Large B Cell Lymphoma (DLBCL) is a heterogenous B-cell malignancy, with each patient presenting with a heavy and diverse burden of alterations in their DNA. Therefore,…
Researcher Spotlight: Rossella Marullo, MD, PhD Joan & Sanford I. Weill Medical College of Cornell University Two genomic studies revealed that 8 to 16 percent of diffuse large B-cell lymphoma (DLBCL) patients harborloss-of-function mutations in the gene TOX (TOXLOF). TOX is a…
Researcher Spotlight: Arushi Khurana, M.B.B.S Mayo Clinic, Rochester, MN More than two-thirds of the newly diagnosed Diffuselarge B-cell lymphoma (DLBCL) patients are excluded from participating in clinical trials, without considering the structural and attitudinal barriers that preclude clinical trial participation. Over the…
Researcher Spotlight: David A. Bond, MD The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital Diffuse large B-cell lymphoma (DLBCL) is the mostcommon type of non-Hodgkin lymphoma (NHL). SinceDLBCL can advance quickly, it usually requires immediatetreatment, which…
Researcher Spotlight: Elisa Mandato, PhD Dana-Farber Cancer Institute Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and the most common hematologic malignancy in the United States. Dr. Mandato’s LRF research project will involve developing…